Close Menu

More articles about Business News

The test, which has Emergency Use Authorization from the US Food and Drug Administration, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes.

Opko's BioReference Laboratories business processed about 2.2 million COVID-19 molecular tests during the quarter, it said.

For the three months ended June 30, the genomic testing firm reported total revenues of $20.7 million.

The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

On a conference call to discuss the company's third quarter financial results, executives said they increased molecular test production by 50 percent during the quarter.

The test was developed by a consortium founded in April by Omega Diagnostics, Abingdon Health, BBI Solutions, CIGA Healthcare, and the University of Oxford.

The lateral flow antibody test kit has a combined IgG/IgM sensitivity of 100 percent and specificity of almost 99 percent and received EUA in June.

Strong demand for the firm's COVID-19 molecular tests for the Panther and Panther Fusion platforms offset revenue declines in other areas of the business.

Intalere member hospitals will receive access to Magnolia's alliance member pricing and clinical performance guarantee for Steripath under the agreement.

MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.

The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.

Under the merger, Brava will operate as the in vitro diagnostics division of MBio, developing a portfolio of point-of-care tests for time-critical illnesses.

Both of the RT-PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in a variety of swab samples and other specimens.

According to the agreement, Access Bio must sell at least 2 million tests by Sept. 30, 2021, to keep its exclusive rights in North America.

The assays are both designed to detect immunoglobulin M and G antibodies against SARS-CoV-2 in blood samples, with results in 10 minutes.

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

The firm's Diagnostics segment revenues shot up 46 percent while its Discovery & Analytical Solutions segment revenues retreated 10 percent.

New offerings from the oncology testing company include Inivita's InvisionFirst-Lung test and the NeoLab solid tumor test.

Enzyre is developing a near-patient platform called Enzypad to measure biomarkers in body fluids. The first application will be the monitoring of hemophilia.